Severe Asthma Covid Vaccine Response Study (SHINE)

November 22, 2021 updated by: University Hospital Southampton NHS Foundation Trust

SHINE: Severe Asthma Covid Vaccine Response Study

This study aims to employ a simple finger-prick home test to detect post vaccination antibody levels. The investigators will compare antibody responses in patients with severe asthma on varying treatment regimes (biologics, daily steroids, inhalers-only) with healthy, age-matched controls to study if the magnitude and range of responses vary between severe asthmatics and healthy individuals.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

SARS-CoV-2 and the resulting COVID-19 pandemic has had a major impact on quality of life in people with severe asthma. Careful isolation and lockdown measures have protected many patients, but with major impacts on wellbeing and mental health. Vaccination opens a "light at the end of the tunnel" by protecting against COVID-19. However, the following questions remain unanswered for Covid vaccination in severe asthma: 1) What are patients' expectations/attitudes towards vaccination? 2) Will vaccines induce good immune responses which protect from Covid-19 infections? The first question is being addressed by a survey created SHARP, a European Clinical Research Collaboration on severe asthma- people with asthma from the UK and Europe will be invited to complete the survey. To complement this, the investigators propose a UK pilot study (carried out in up to four severe asthma centres) to measure immune responses following vaccination in 200 people with severe asthma. The investigators will invite 120 people receiving asthma biologics (monoclonal antibodies), 40 people receiving asthma inhalers, 40 people needing daily steroid tablets to control their asthma, and 50 age-matched healthy people. Immune responses will be studied using a simple home blood antibody test posted to participants. By pricking their finger, patients will collect 5-6 drops of blood in a small test tube and will post back on the same day to a laboratory in London. Tests will be done twice: after the first and second vaccine doses.

The study will help us understand if the body's immune response to the COVID-19 vaccine is different in people with severe asthma who are on different treatments to manage their symptoms.

Study Type

Observational

Enrollment (Anticipated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United Kingdom
      • Exeter, United Kingdom, EX2 5DW
        • Not yet recruiting
        • Royal Devon and Exeter NHS Foundation Trust
        • Contact:
        • Contact:
        • Principal Investigator:
          • Matthew Masoli
      • Glasgow, United Kingdom, G12 0YN
      • London, United Kingdom, SE1 9RT
      • Newcastle, United Kingdom, NE1 4LP
        • Not yet recruiting
        • The Newcastle upon Tyne Hospitals NHS Foundation Trust
        • Principal Investigator:
          • Simon Doe
        • Contact:
        • Contact:
    • Hampshire
      • Southampton, Hampshire, United Kingdom, SO16 6YD
        • Recruiting
        • University Hospital Southampton NHS Foundation Trust
        • Contact:
        • Principal Investigator:
          • Hitasha Rupani

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 100 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study will recruit patients that attended the severe asthma clinic. To recruit age-matched controls we will randomly approach the patients and ask if their partners (or age-matched family members or friends) would like to participate in the study.

Description

Inclusion criteria:

  1. Age ≥ 16 years

  2. For asthma patients:

    1. Diagnosis of severe asthma (based on ATS/ERS consensus criteria)
    2. Group A: Currently receiving an asthma biologic with treatment having started at least 3 months before first COVID-19 vaccine
    3. Group B: on maintenance oral steroids at a dose of ≥5mg prednisolone (or equivalent) per day (at the time of first COVID-19 vaccine)
    4. Group C: not on asthma biologic or maintenance oral steroids (at the time of vaccination) or stopped ≥3 months prior to first COVID-19 vaccine

Exclusion criteria:

  1. Current pregnancy or planning a pregnancy within the next 6 months
  2. Current malignancy
  3. Diagnosis of immunodeficiency requiring treatment

  4. Additional exclusion criteria for asthma patients:

    1. Group A: maintenance oral steroids at the time of first COVID-19 vaccine
    2. Group B: on an asthma biologic at the time of first COVID-19 vaccine

  5. Additional exclusion criteria for healthy controls cohort (as assessed by research team):

    1. No history of asthma or significant other lung disease
    2. Severe chronic inflammatory disease
    3. Severe cardiac disease
    4. Diabetes
  6. Previous proven COVID-19 infection
  7. Inability to provide informed consent
  8. Unwilling to have vaccination
  9. Participation in another clinical trial involving an investigational medicinal product (IMP).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Asthma biologics
120 people receiving asthma biologics (monoclonal antibodies)
Other: Not Interventional their treatments are their routine NHS care
Not Interventional their treatments are their routine NHS care
Asthma inhalers
40 people receiving asthma inhalers
Other: Not Interventional their treatments are their routine NHS care
Not Interventional their treatments are their routine NHS care
Steroid tablets
40 people needing daily steroid tablets to control their asthma
Other: Not Interventional their treatments are their routine NHS care
Not Interventional their treatments are their routine NHS care
Healthy Control
50 age-matched healthy people
Other: Not Interventional their treatments are their routine NHS care
Not Interventional their treatments are their routine NHS care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measured immune response
Time Frame: 12 Months
To compare the measured immune response to vaccination in patients with 200 severe asthma and 50 healthy individuals. A positive response will be defined as IgG ≥0.201.
12 Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Range of immune responses
Time Frame: 12 Months
To evaluate the range of immune responses measured by IgG titres (very high: >1.25, high: 0.751-1.25, medium: 0.401-0.75 or low: 0.201-0.4) in patients with 200 severe asthma and compare this with 50 healthy individuals
12 Months
Differences in responses between treatment groups
Time Frame: 12 Months
To identify any differences in responses between patients treated with biologics, standard inhaler treatment with/without maintenance oral corticosteroids (mOCS)
12 Months
Differences between responses within the three biologics
Time Frame: 12 Months
To identify any differences between responses to vaccines amongst patient groups treated with three biologics (anti-IgE Omalizumab, anti-IL-5 Mepolizumab, and anti-IL-5receptor Benralizumab)
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital Southampton NHS Foundation Trust

Collaborators

Asthma Allergy & Inflammation Research Trust

Investigators

  • Principal Investigator: Hitasha Rupani, University Hospital Southampton NHS Foundation Trust

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 6, 2021

Primary Completion (Anticipated)

March 1, 2022

Study Completion (Anticipated)

March 1, 2022

Study Registration Dates

First Submitted

May 7, 2021

First Submitted That Met QC Criteria

November 22, 2021

First Posted (Actual)

November 23, 2021

Study Record Updates

Last Update Posted (Actual)

November 23, 2021

Last Update Submitted That Met QC Criteria

November 22, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RHM MED1777

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronavirus Antibody Levels

Clinical Trials on Not Interventional their treatments are their routine NHS care

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe